GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Earnings per Share (Diluted)

AIM ImmunoTech (STU:HXB2) Earnings per Share (Diluted) : €-0.59 (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Earnings per Share (Diluted)?

AIM ImmunoTech's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.11. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.59.

AIM ImmunoTech's EPS (Basic) for the three months ended in Mar. 2024 was €-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.59.

AIM ImmunoTech's EPS without NRI for the three months ended in Mar. 2024 was €-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.59.

During the past 3 years, the average EPS without NRIGrowth Rate was -10.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 46.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.70% per year.

During the past 13 years, AIM ImmunoTech's highest 3-Year average EPS without NRI Growth Rate was 70.20% per year. The lowest was -19.70% per year. And the median was 15.35% per year.


AIM ImmunoTech Earnings per Share (Diluted) Historical Data

The historical data trend for AIM ImmunoTech's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Earnings per Share (Diluted) Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.32 -0.37 -0.35 -0.38 -0.55

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.09 -0.15 -0.24 -0.11

Competitive Comparison of AIM ImmunoTech's Earnings per Share (Diluted)

For the Biotechnology subindustry, AIM ImmunoTech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's PE Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's PE Ratio falls into.



AIM ImmunoTech Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

AIM ImmunoTech's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-26.558-0)/48.585
=-0.55

AIM ImmunoTech's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-5.352-0)/49.458
=-0.11

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


AIM ImmunoTech  (STU:HXB2) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


AIM ImmunoTech Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines